Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Kenichiro, Kawakado, Keita, Kawajiri, Tomoka, Nishi, Tatsuya, Makimoto, Go, Tamura, Tomoki, Kuyama, Shoichi, Tanimoto, Mitsune
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434540/
https://www.ncbi.nlm.nih.gov/pubmed/32296006
http://dx.doi.org/10.2169/internalmedicine.4449-20
_version_ 1783572169378234368
author Kudo, Kenichiro
Kawakado, Keita
Kawajiri, Tomoka
Nishi, Tatsuya
Makimoto, Go
Tamura, Tomoki
Kuyama, Shoichi
Tanimoto, Mitsune
author_facet Kudo, Kenichiro
Kawakado, Keita
Kawajiri, Tomoka
Nishi, Tatsuya
Makimoto, Go
Tamura, Tomoki
Kuyama, Shoichi
Tanimoto, Mitsune
author_sort Kudo, Kenichiro
collection PubMed
description The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.
format Online
Article
Text
id pubmed-7434540
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-74345402020-08-27 Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib Kudo, Kenichiro Kawakado, Keita Kawajiri, Tomoka Nishi, Tatsuya Makimoto, Go Tamura, Tomoki Kuyama, Shoichi Tanimoto, Mitsune Intern Med Case Report The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases. The Japanese Society of Internal Medicine 2020-04-16 2020-07-15 /pmc/articles/PMC7434540/ /pubmed/32296006 http://dx.doi.org/10.2169/internalmedicine.4449-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kudo, Kenichiro
Kawakado, Keita
Kawajiri, Tomoka
Nishi, Tatsuya
Makimoto, Go
Tamura, Tomoki
Kuyama, Shoichi
Tanimoto, Mitsune
Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
title Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
title_full Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
title_fullStr Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
title_full_unstemmed Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
title_short Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
title_sort dramatic response of brain metastasis from egfr-mutation-positive nsclc to dacomitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434540/
https://www.ncbi.nlm.nih.gov/pubmed/32296006
http://dx.doi.org/10.2169/internalmedicine.4449-20
work_keys_str_mv AT kudokenichiro dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT kawakadokeita dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT kawajiritomoka dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT nishitatsuya dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT makimotogo dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT tamuratomoki dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT kuyamashoichi dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib
AT tanimotomitsune dramaticresponseofbrainmetastasisfromegfrmutationpositivensclctodacomitinib

Ejemplares similares